<DOC>
	<DOC>NCT02137915</DOC>
	<brief_summary>This study is being done to determine the long-term safety and possible benefits of transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic Atrophy of Age-Related Macular Degeneration. This long-term follow-up study is limited to those individuals who received a transplant of HuCNS-SC cells into one of their eyes as part of the CL-N01-AMD study. No additional study product will be given in this 4-year long-term follow-up study.</brief_summary>
	<brief_title>Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Must have completed Study CLN01AMD Must be able to provide written informed consent prior to any study related procedures Agree to comply in good faith with all conditions of the study and to attend all required study visits Inability to comply with study procedures or visits Since enrolling in Study CLN01AMD, have entered, or are about to enter another investigational study that, in the opinion of the Principal Investigator (PI), might confound study interpretation. Received offstudy immunosuppressive agents in the leadin study or are receiving any immunosuppressive agents since completing the leadin study</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>AMD</keyword>
</DOC>